Table 4 Patients’ characteristics by AGU
AGU 1 (n= 172) | AGU 2 (n= 215) | AGU 3 (n= 174) | |
|---|---|---|---|
Demographic data | |||
Age (years): mean; SD | 86.7; 5.6 | 84.4; 5.7 | 85.1; 6.2 |
Female | 123 (71.5%) | 143 (66.5%) | 126 (72.4%) |
Comorbidities | |||
CIRS-G: median; Q1-Q3 | 20; 17-23 | 24; 20-28 | 20.5; 17-24.75 |
Anxiety | 10 (5.8%) | 59 (27.4%) | 23 (13.2%) |
Sleep disorder | 5 (2.9%) | 26 (12.1%) | 18 (10.3%) |
Restless leg syndrome | 1 (0.6%) | 11 (5.1%) | 4 (2.3%) |
Depression | 33 (19.2%) | 63 (29.3%) | 53 (30.5%) |
Extrapyramidal syndrome | 13 (7.6%) | 25 (11.6%) | 20 (11.5%) |
COPD | 23 (13.4%) | 34 (15.8%) | 25 (14.4%) |
Cognitive decline | 129 (75.0%) | 83 (38.6%) | 104 (59.8%) |
Delirium | 55 (32.0%) | 76 (35.3%) | 57 (32.8%) |
Fall at admission | 77 (44.8%) | 112 (52.1%) | 85 (48.9%) |
Current fracture | 22 (12.8%) | 30 (14.0%) | 33 (19.0%) |
Previous fracture | 60 (34.9%) | 83 (38.6%) | 58 (33.3%) |
Psychiatric disorder | 3 (1.7%) | 5 (2.3%) | 8 (4.6%) |
Administrative data | |||
Place of residence: | |||
Home | 122 (70.9%) | 169 (78.6%) | 121 (69.5%) |
Nursing home | 50 (29.1%) | 46 (21.4%) | 53 (30.5%) |
Length of stay (days): median; Q1-Q3 | 15; 11.75-20 | 15; 11-21.5 | 16; 11-26 |
Admission route: | |||
Emergency | 146 (84.9%) | 116 (54.0%) | 124 (71.3%) |
Direct | 15 (8.7%) | 70 (32.6%) | 25 (14.4%) |
Transfer | 11 (6.4%) | 29 (13.5%) | 25 (14.4%) |
Discharge destination: | |||
Home | 88 (51.2%) | 108 (50.2%) | 81 (46.6%) |
Nursing home | 61 (35.5%) | 68 (31.6%) | 71 (40.8%) |
Another ward | 23 (13.4%) | 39 (18.1%) | 22 (12.6) |
Medications at admission | |||
Total medications: median; Q1-Q3 | 8.5; 6-10.25 | 10; 8-13 | 8; 6-11 |
Polypharmacy | 149 (86.6%) | 206 (95.8%) | 159 (91.4%) |
Excessive polypharmacy | 63 (36.6%) | 122 (56.7%) | 65 (37.4%) |
BZRA dose: median; Q1-Q3 | 1.3; 1-2.5 | 1; 0.95-2 | 1; 0.85-2 |
Multi-BZRA users | 29 (16.9%) | 51 (23.7%) | 32 (1.8%) |
Psychotropic drug users | 119 (69.2%) | 157 (73.0%) | 123 (70.7%) |
Psychotropic polypharmacy | 69 (40.1%) | 97 (45.1%) | 65 (37.4%) |
Antipsychotic users | 39 (22.7%) | 43 (20.0%) | 34 (19.5%) |
Antidepressant users | 76 (44.2%) | 118 (54.9%) | 79 (45.4%) |
Trazodone users | 13 (7.6%) | 30 (14.0%) | 16 (9.2%) |
Miscellaneous | |||
Palliative status | 10 (5.8%) | 8 (3.7%) | 24 (13.8%) |
Intervention of a clinical pharmacist | 0 (0.0%) | 202 (94.0%) | 0 (0.0%) |
Identification of a BZRA-related adverse event by the treating physician | 11 (6.4%) | 51 (23.7%) | 26 (14.9%) |
BZRA switch between admission and discharge | 11 (6.4%) | 22 (10.2%) | 32 (18.4%) |